Results 11 to 20 of about 12,458,805 (285)

ZSM-5-5-FU as a Drug Delivery Platform for 5-Fu

Biomedical Journal of Scientific & Technical Research, 2022
The drug delivery application of Porous metal–organic frameworks (MOFs) have been investigated due to their unique structures which are built of inorganic nodes and organic ligands. In present study, zsm-5-5-FU was successfully prepared by applied for delivery of 5-fluorouracil (5-FU). Using variety of analytical methods including FTIR, FESEM, EDS, and
Pourya Zarshenas
openaire   +2 more sources

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs [PDF]

Cancers, 2010
5-Fluorouracil (5-FU) is a key anticancer drug that for its broad antitumor activity, as well as for its synergism with other anticancer drugs, has been used to treat various types of malignancies. In chemotherapeutic regimens, 5-FU has been combined with oxaliplatin, irinotecan and other drugs as a continuous intravenous infusion.
Miura, Koh, Kinouchi, Makoto, Ishida, Kazuyuki, Fujibuchi, Wataru, Naitoh, Takeshi, Ogawa, Hitoshi, Ando, Toshinori, Yazaki, Nobuki, Watanabe, Kazuhiro, Haneda, Sho, Shibata, Chikashi, Sasaki, Iwao   +11 more
openaire   +3 more sources

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation [PDF]

Scientific Reports, 2019
AbstractChemoresistance to 5-fluorouracil (5-Fu)-based chemotherapy is a leading obstacle in achieving effective treatment for colorectal cancer (CRC). Typically, NF-κB activation induced by the chemotherapeutics themselves is an important cause resulting in chemoresistance.
Fu Jinbo, Xu Yiming, Yang Yushan, Liu Yun, Ma Lulu, Zhang Yiyao   +5 more
openaire   +5 more sources

Kinetic modeling of 5-FU-loaded SLNs.

, 2023
The present study aimed to prepare solid lipid-based nanoparticles (SLNs) using Precirol® ATO 5 as solid lipid and Poloxamer 188 and Tween 80 as surfactant and co-surfactant respectively, and SLNs-derived gel for sustained delivery, enhanced in-vitro ...
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.

, 2023
Permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Rheograms of 5-FU plain gel and 5-FU-loaded SLNs gel.

, 2023
Rheograms of 5-FU plain gel and 5-FU-loaded SLNs gel.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial [PDF]

, 2006
Oral capecitabine (Xeloda^®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer.
F Coxon, T S Maughan, Douillard, J.Y., Lesniewski-Kmak, K, Bertetto, O., Jelic, S., Maughan, T.S., Dufour, A., J-Y Douillard, Johnston, P G, C Twelves, Díaz-Rubio, E., Cassidy, J, Twelves, C., Jelic, S, P G Johnston, Figer, A, G Fountzilas, W Scheithauer, Patel, K K, Malzyner, A, Fountzilas, G., K Lesniewski-Kmak, A Malzyner, Maughan, TS, Bustová, I, Cowell, W., Garrison, L.P., Twelves, C, Díaz-Rubio, E, O Bertetto, W Cowell, Beham, A, S Jelic, Maughan, Tim, Dufour, P, J J McKendrick, Scheithauer, W., Douillard, JY, Cowell, W, Lesniewski-Kmak, K., Garrison, L P, Bustová, I., Beham, A., Fountzilas, G, Johnston, PG, A Beham, Garrison, LP, K K Patel, Patel, KK, I Bustová, Cassidy, J., McKendrick, J.J., Bertetto, O, L P Garrison, Coxon, F., Patel, K.K., Douillard, J-Y, P Dufour, A Figer, Johnston, P.G., Scheithauer, W, Coxon, F, Maughan, T S, McKendrick, JJ, J Cassidy, E Díaz-Rubio, McKendrick, J J, Malzyner, A., Figer, A.   +69 more
core   +1 more source

Ex-vivo permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.

, 2023
Ex-vivo permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Physicochemical characteristics of 5-FU-loaded SLNs.

, 2023
Physicochemical characteristics of 5-FU-loaded SLNs.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Uio-67-5-Fu as A Drug Delivery Platform for 5-Fu

Journal of Chemistry & its Applications, 2022
The drug delivery application of Porous metal–organic frameworks (MOFs) have been investigated due to their unique structures which are built of inorganic nodes and organic ligands. In present study, Uio-67-5-FU was successfully prepared by applied for delivery of 5-fluorouracil (5-FU).
openaire   +2 more sources